600529 山东药玻
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,824,9514.12%4,982,1984,187,2793,875,3053,427,069
减:营业总成本2,966,9640.59%4,070,1673,448,3573,159,6172,730,129
    其中:营业成本2,597,119-1.53%3,585,4993,063,2672,727,5612,277,074
               财务费用(25,023)-12.87%(35,668)(43,972)(1,311)5,699
               资产减值损失(30,163)165.95%(42,308)(40,203)(38,132)(38,486)
公允价值变动收益19,84417.19%22,8293,7319,261504
投资收益9,220-39.98%18,3991,7193,55115,901
    其中:对联营企业和合营企业的投资收益------------
营业利润873,19617.71%916,367711,069698,289677,253
利润总额872,19919.32%910,824708,051688,718653,484
减:所得税费用151,76830.03%135,02289,76497,62989,044
净利润720,43117.29%775,802618,287591,088564,440
减:非控股权益------------
股东净利润720,43117.29%775,802618,287591,088564,440

市场价值指针
每股收益 (元) *1.08617.29%1.1701.0300.9900.950
每股派息 (元) *0.300--0.4000.3000.3000.300
每股净资产 (元) *11.7355.59%11.35410.4917.8507.153
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容